Skip to main content

Biologics in Inflammatory Bowel Disease, An issue of Gastroenterology Clinics of North America

  • 1st Edition, Volume 43-3 - August 13, 2014
  • Author: Edward V. Loftus Jr
  • Language: English
  • Hardback ISBN:
    9 7 8 - 0 - 3 2 3 - 3 2 3 2 5 - 3
  • eBook ISBN:
    9 7 8 - 0 - 3 2 3 - 3 2 3 2 6 - 0

By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration fo… Read more

Biologics in Inflammatory Bowel Disease, An issue of Gastroenterology Clinics of North America

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.